Fig. 2
From: Nonsteroidal sulfamate derivatives as new therapeutic approaches for Neurofibromatosis 2 (NF2)
Cell viability of NF2-null and NF2-wild type tumour cells in response to the 2ME non-steroidal sulfamate derivatives STX3451 and STX2895. DMSO; STX3451 0.1 μM; STX3451 0.3 μM; STX3451 0.6 μM; STX3451 1 μM; STX2895 0.1 μM; STX2895 0.3 μM; STX2895 0.6 μM; STX2895 1 μM. Graphs show the increase in absorbance (fold change) after 4 days of treatment compared to the levels at the beginning of the treatment